Medical Advocates

Tenofovir Disoproxil Fumarate
(Viread)
   
Journal Citations: Adverse Events

Cellular Disorders
Blood Disorders
Cardiovascular Disorders
Cutaneous Disorders
Metabolic Disorders
Mitochondrial Toxicity
Musculoskeletal Disorders
Pancreatic Disorders
Renal Disorders

Thyroid Disorders
 


Tenofovir Main Page Main New/Newsworthy  Home Page      

Last Update:  May 04, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 

  A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Tenofovir nephrotoxicity: 2011 update.

Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al
AIDS Res Treat
. 2011;2011:354908.
Paper

Cellular Disorders
 

 

Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other
nucleoside reverse transcriptase inhibitors.

Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ.  et al
Antiviral Res 2002 Apr;54(1):37-45
Abstract
 
FULL-TEXT ARTICLE
Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir:
Comparison with Other Nucleoside Reverse Transcriptase Inhibitors.

Birkus G, Hitchcock MJ, Cihlar T. et al.
Antimicrob Agents Chemother 2002 Mar;46(3):716-723

Paper


Blood Disorders
 

 
FULL-TEXT ARTICLE
Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with hiv infection.
Aperis G, Paliouras C, Zervos A, et al
J Ren Care. 2011 Mar;37(1):25-9.
Abstract

Minor changes in calculated creatinine clearance and anion-gap are associated with
tenofovir disoproxil fumarate-containing highly active antiretroviral therapy.
Winston A, Amin J, Mallon P, Marriott D, et al
HIV Med. 2006 Mar;7(2):105-111.
Abstract
 

Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed
HIV-infected out-patients receiving highly active antiretroviral therapy.
Buchacz K, Brooks JT, Tong T, et al 

HIV Med. 2006 Oct;7(7):451-6.
Abstract

Hypokalemia in HIV patients on tenofovir.
Cirino CM, Kan VL 
Kan V
AIDS.
2006 Aug 1;20(12):1671-

Abstract


Cardiovascular Disorders
 

  FULL-TEXT PDF ARTICLE
Evaluation of Cardiovascular biomarkers In HIV-infected Patients Switching to Abacavir or
Tenofovir Based Therapy
Rasmussen TA, Tolstrup M, Melchjorsen J,  et al
BMC Infectious Diseases
2011, 11:267
Paper

Impact of Tenofovir Versus Abacavir on HIV-Related Endothelial Dysfyunction.
Francisci D, Falcinelli E, Belfiori B,  et al 
AIDS Patient Care STDS. 2011 Aug 18
Abstract

Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected
persons.
Choi AI, Vittinghoff E, Deeks SG,  et al
AIDS
. 2011 Apr 21.
Abstract

A WEEK-IN-REVIEW-FEATURED REPORT
FULL-TEXT PDF ARTICLE

Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating
antiretroviral therapy with abacavir or tenofovir.
Padilla S, Masia M, Garcia N, et al
BMC Infect Dis
. 2011 Feb 4;11(1):40

Paper


Cutaneous Disorders
 

  Cutaneous reactions with tenofovir disoproxil fumarate: a report of nine cases.
Lockhart SM, Rathbun RC, Stephens JR, et al

AIDS
. 2007 Jun;21(10):1370-3.

Abstract

Metabolic Disorders
 

 
From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic
parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.
Curran A, Ribera E.
Expert Opin Drug Saf. 2011 Jan 17.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable
background antiretroviral therapy: ACTG 5206.
T
ungsiripat M, Kitch D, Glesby MJ,  et al
AIDS
. 2010 Jul 17;24(11):1781-4.
Abstract

Metabolic and Anthropometric Changes One Year after Switching from Didanosine/Stavudine
to Tenofovir in HIV-infected Patients.

Claas GJ, Julg B, Goebel FD, Bogner JR.
Eur J Med Res. 2007 Feb 26;12(2):54-60.

Abstract


Mitochondrial Toxicity
       

  Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with
additional nucleoside reverse transcriptase inhibitors.

Venhoff N, Setzer B, Melkaoui K, Walker UA.
Antivir Ther. 2007;12(7):1075-85.

Abstract

Musculoskeletal Disorders
 

 
A WEEK-IN-REVIEW FEATURED ARTICLE
FULL-TEXT ARTICLE

Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy
in a Randomized Trial.
Rasmussen TA, Jensen D, Tolstrup M, et al
PLoS One
. 2012;7(3):e32445.
Paper

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.
Bedimo R, Maalouf NM, Zhang S,  et al
AIDS
. 2012 Feb 1
Abstract

Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus
non-tenofovir regimens.
Brown TT, Ross AC, Storer N, et al
Antivir Ther
. 2011;16(7):1063-72.
Abstract

Endocrine complications of human immunodeficiency virus infection: Hypogonadism, bone disease
and tenofovir-related toxicity.
Cotter AG, Powderly WG.
Best Pract Res Clin Endocrinol Metab
. 2011
Abstract

Normal plasma FGF23 levels kinetic in tenofovir-related hypophosphatemic osteomalacia
in an HIV-infected patient with von Recklinghausen disease.
Saidenberg-Kermanac'h N, Souabni L, Prendki V,et al
Joint Bone Spine
. 2010 Dec 22.
Abstract

Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort
of HIV-infected youths.
Viganò A, Zuccotti GV, Puzzovio M,  et al
Antivir Ther
. 2010;15(7):1053-8.
Abstract

Tenofovir-associated severe bone pain: I cannot walk!
Jhaveri MA, Mawad HW, Thornton AC,et al
J Int Assoc Physicians AIDS Care
2010 Sep-Oct;9(5):328-34.
Abstract

Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications
for bone mineral density loss.
Grigsby IF, Pham L, Mansky LM, et al 

Biochem Biophys Res Commun
. 2010 Feb 17
Abstract

Tenofovir-associated bone density loss.
Grigsby IF, Pham L, Mansky LM, et al

Ther Clin Risk Manag
. 2010 Feb 2;6:41-
Abstract

Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report.
Di Biagio A, Rosso R, Monteforte P, et sl
J Med Case Reports. 2009 Jul 22;3:8136
Abstract

Tenofovir-associated renal and bone toxicity.
Woodward CL, Hall AM, Williams IG,
HIV Med. 2009 May 6.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
The development of hypophosphataemic osteomalacia with myopathy in two patients with
HIV infection receiving tenofovir therapy.
Parsonage MJ, Wilkins E, Snowden N, et al
HIV Med. 2005 Sep;6(5):341-6.
Abstract


Pancreatic Disorders
 

 
Acute Onset of Pancreatitis with Concomitant Use of Tenofovir and Didanosine.A
Kirian MA, Higginson RT, Fulco PP.
Ann Pharmacother. 2004 Aug 31
Abstract
 
Pancreatitis treated with didanosine and tenofovir disoproxil fumarate.
Blanchard JN, Wohlfeiler M, Canas A, et al 
Clin Infect Dis. 2003 Sep 1;37(5):e57-62.
Abstract

Renal Disorders
 

 
Renal Toxicity of Long-Term Therapy With Tenofovir in HIV-Infected Patients.
Monteagudo-Chu MO, Chang MH, et al
J Pharm Pract
. 2012 May 2.
Abstract

A WEEK-IN-REVIEW FEATURED ARTICLE
Similar Risk of Renal Events Among Patients Treated with Tenofovir or Entecavir for Chronic Hepatitis B.
Gish RG, Clark MD, Kane SD, et al
Clin Gastroenterol Hepato
l
. 2012 Apr 13.
Abstract

A WEEK-IN-REVIEW FEATURED ARTICLE
FULL-TEXT ARTICLE

Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy
in a Randomized Trial.
Rasmussen TA, Jensen D, Tolstrup M, et al
PLoS One
. 2012;7(3):e32445.
Paper

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Young J, Schäfer J, Fux CA,  et al
AIDS
. 2012 Mar 13;26(5):567-575
Abstract

Association of tenofovir exposure with kidney disease risk in HIV infection.
Scherzer R, Estrella M, Li Y, et al
AIDS
. 2012 Feb 4
Abstract

FULL-TEXT PDF ARTICLE
Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate
and protease inhibitors.
Pontrelli G, Cotugno N, Amodio D,  et al
BMC Infect Di
s
. 2012 Jan 23;12(1):18.
Paper

FULL-TEXT ARTICLE
Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body
Weight Treatment-Naïve Patients with HIV Infection.

Nishijima T, Gatanaga H, Komatsu H, et al
PLoS One
. 2012;7(1):e29977.
Paper

Early Markers of Tubular Dysfunction in Antiretroviral-Experienced HIV-Infected Patients Treated with Tenofovir Versus Abacavir.
Maggi P, Montinaro V, Bellacosa C,  et al
AIDS Patient Care STDS
. 2012 Jan;26(1):5-11.
Abstract

Fanconi syndrome-like tubular acidosis associated with a tenofovir-containing antiretroviral regimen in a
human immunodeficiency virus-1-infected Asian woman.
Kiyasu Y, Koganemaru H, Hitomi S.
J Infect Chemother
.
2011 Sep 15
Abstract

Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular
rather than glomerular toxicity.
Vrouenraets SM, Fux CA, Wit FW, et al
AIDS. 2011 Aug 19
Abstract

FULL-TEXT ARTICLE
Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-Infected Patients:
A Retrospective Cohort Study of Japanese Patients.

Nishijima T, Komatsu H, Gatanaga H, et al
PLoS One
. 2011;6(7):e22661.
Paper


A WEEK-IN-REVIEW FEATURED REPORT

Severe Acute Renal Failure in an HIV-Infected Patient After Only 2 Weeks of Tenofovir-Based Antiretroviral Therapy.
Pavie J, Scemla A, Bouldouyre MA, et al
AIDS Patient Care STDS
. 2011 Jul 13.
Abstract

A comparison of tenofovir-associated renal function changes in HIV-infected African Americans vs
Caucasians.

Lao CK, Gruta C, John MD, Cocohoba J.
J Natl Med Assoc. 2011 Jun;103(6):518-22.

Abstract

Subcellular renal proximal tubular mitochondrial toxicity with tenofovir treatment.
Kohler JJ, Hosseini SH.
Methods Mol Biol
. 2011;755:267-77.
Abstract

Tenofovir nephrotoxicity: 2011 update.
Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al
AIDS Res Treat
. 2011;2011:354908.
Abstract

Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: |
Role of intracellular tenofovir diphosphate levels and review of the literature.
Haverkort ME, van der Spek BW, Lips P, et al 
Scand J Infect Dis
. 2011 May 12
Abstract

Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
Calza L, Trapani F, Tedeschi S, et al
Scand J Infect Dis
. 2011 Apr 1
Abstract

Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence.
Hall AM, Hendry BM, Nitsch D, Connolly JO.
Am J Kidney Dis. 2011 Mar 22
Abstract

FULL-TEXT ARTICLE
Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort
in rural Lesotho.
Bygrave H, Kranzer K, Hilderbrand K,   et al
PLoS One
. 2011 Mar 2;6(3):e17609.
Paper

Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transporters.
Kohler JJ, Hosseini SH, Green E. et al
Lab Invest. 2011 Mar 14
Abstract

Low incidence of renal impairment observed in tenofovir-treated patients.
O'Donnell EP, Scarsi KK, Darin KM
J Antimicrob Chemother. 2011 Feb 17.
Abstract

Tenofovir-induced kidney disease: an acquired renal tubular mitochondriopathy.
Perazella MA.  
Kidney Int
. 2010 Dec;78(11):1060-3.
Abstract

Incidence and Risk Factors for Tenofovir-associated Renal Function Decline among Thai
HIV-infected Patients with Low-body Weight.
Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S.
Curr HIV Res
. 2010 Oct 1;8(7):504-9.
Abstract

Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast.
Ondounda M, Tanon A, Ehui E,  et al
Med Mal Infect. 2010 Sep 8
Abstract

Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and
mitochondrial abnormalities.
Herlitz LC, Mohan S, Stokes MB,  et al
Kidney Int. 2010 Sep 1
Abstract

Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in
HIV-infected patients.

Cooper RD, Wiebe N, Smith N, et al
Clin Infect Dis
. 2010 Sep 1;51(5):496-505.
Abstract

Renal toxicity associated with tenofovir use.
Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V.
Expert Opin Drug Saf
. 2010 Jul;9(4):545-59
Abstract

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz,
in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT
Study.
Post FA, Moyle GJ, Stellbrink HJ,  et al  
J Acquir Immune Defic Syndr
. 2010 Apr 24
Abstract

Impairment in kidney tubular function in patients receiving tenofovir is associated
with higher tenofovir plasma concentrations.
Rodríguez-Nóvoa S, Labarga P, Davolio A, et al
AIDS
. 2010 Mar 17
Abstract

Incomplete Reversibility of Tenofovir-Related Renal Toxicity in HIV-Infected Men.
Wever K, van Agtmael MA, Carr A.
 
J Acquir Immune Defic Syndr
. 2010 Feb 19.
Abstract

Acute renal failure and hypercalcemia in an AIDS patient on tenofovir and low-dose
vitamin d therapy with immune reconstitution inflammatory syndrome.
Lavae-Mokhtari M, Mohammad-Khani S, Schmidt RE, Stoll M.

Med Klin (Munich)
. 2009 Oct 15;104(10):810-3
Abstract

Impact of Tenofovir on Renal Function in HIV-Infected Antiretroviral Naïve Patients.
Horberg M, Tang B, Towner W, et al
J Acquir Immune Defic Syndr. 2009 Oct 15
Abstract

Tenofovir-associated renal and bone toxicity.
Woodward CL, Hall AM, Williams IG,
HIV Med. 2009 May 6.
Abstract

Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir:
A Pharmacogenetic Study.

Rodríguez-Nóvoa S, Labarga P, Soriano V,  et al
Clin Infect Dis. 2009 Apr 28 .
Abstract

Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
Kinai E, Hanabusa H. 

AIDS Res Hum Retroviruses
. 2009 Apr;25(4):387-94.
Abstract

Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and
diabetes insipidus: a report of 3 cases.
Irizarry-Alvarado JM, Dwyer JP,
et sl
AIDS Read
. 2009 Mar;19(3):114-2
Abstract
 

Tenofovir renal toxicity targets mitochondria of renal proximal tubules.
Kohler JJ, Hosseini SH, Hoying-Brandt A, et al
Lab Invest. 2009 Mar 9
Abstract
 
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated
with tenofovir.
Labarga P, Barreiro P, Martin-Carbonero L, et al  

AIDS
. 2009 Mar 2
Abstract
 
Tenofovir-Associated Nephrotoxicity in Two HIV-Infected Adolescent Males.
Wood SM, Shah SS, Steenhoff AP, et al

AIDS Patient Care STDS
. 2009 Jan;23(1):1-4.
Abstract
 
Glomerular filtration rates in HIV-infected patients treated with and without tenofovir:
a prospective, observational study.
Guaraldi G, Roverato A, Giovanardi C, et al
J Antimicrob Chemother. 2008 Dec 17.
Abstract
 
A WEEK IN REVIEW FEATURED REPORT
A case of acute renal failure involving high amounts of tenofovir after HAART start
Yoshimoto E, Konishi M, Uno K, et al 

Kansenshogaku Zasshi
. 2008 Nov;82(6):650-3.
Abstract
 
Renal Dysfunction and Tenofovir Toxicity in HIV-infected Patients.
Szczech LA

Top HIV Med
. 2008 Oct-Nov;16(4):122-6.
Abstract
 
Rosiglitazone reverses tenofovir-induced nephrotoxicity.
Libório AB, Andrade L, Pereira LV, et al
Kidney Int. 2008 Jun 18
Abstract
 
FULL-TEXT PDF ARTICLE
Acute renal failure in an AIDS patient on tenofovir: a case report.
Kapitsinou PP, Ansari N 
J Med Case Reports.
2008 Mar 31;2(1):94
Paper
 
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
Gupta SK. 

AIDS Patient Care STDS.
2008 Feb;22(2):99-103.
Abstract
 
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the
Swiss HIV Cohort Study.

Fux CA, Simcock M, Wolbers M, et al 
Antivir Ther. 2007;12(8):1165-73.
Abstract
 
Greater Tenofovir-Associated Renal Function Decline with Protease Inhibitor-Based versus
Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy.

Goicoechea M, Liu S, Best B, et al 
J Infect Dis. 2008 Jan 1;197(1):102-108.
Abstract
 
Acute renal failure after initiation of tenofovir disoproxil fumarate.
Hynes P, Urbina A, McMeeking A, et al 

Ren Fail
. 2007;29(8):1063-6.
Abstract
 
Early onset of tenofovir-induced renal failure: case report and review of the literature.
Patel SM, Zembower TR, Palella F, et al

ScientificWorldJournal
. 2007 Jul 27;7:1140-8
Abstract
 
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
Brim NM, Cu-Uvin S, Hu SL, O'Bell JW.

AIDS Read.
2007 Jun;17(6):322-8, C3.
Abstract
 
Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project.
Madeddu G, Bonfanti P, De Socio GV, et al
Biomed Pharmacother. 2007 May 29;
Abstract
 
Renal Function in Tenofovir-Exposed and Tenofovir-Unexposed Patients Receiving Highly Active
Antiretroviral Therapy in the HIV Outpatient Study.

Young B, Buchacz K, Baker RK, et al

J Int Assoc Physicians AIDS Care
2007 Jun 19
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy
in a retrospective analysis of kidney biopsies.

Schmid S, Opravil M, Moddel M, et al

Virchows Arch
. 2007 Apr 27;
Abstract
 
Tenofovir-induced kidney injury.
Gitman MD, Hirschwerk D, Baskin CH, Singhal PC.

Expert Opin Drug Saf.
2007 Mar;6(2):155-164.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy.
Izzedine H, Hulot JS, Villard E, et al

J Infect Dis. 2006 Dec 1;194(11):1481-91.
Abstract

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.
Zimmermann AE, Pizzoferrato T, Bedford J, et al
Clin Infect Dis. 2006 Jan 15;42(2):283-90.
Abstract

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.
Zimmermann AE, Pizzoferrato T, Bedford J, et al  
Clin Infect Dis.
2006 Jan 15;42(2):283-90.
Abstract
 
Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in
HIV-positive adults?
Badiou S, Merle De Boever C, Terrier N, et al 

J Infect.
2005 Sep 19;
Abstract
 
Low frequency of renal function impairment during one-year of therapy with tenofovir-containing
regimens in the real-world: a case-control study.
Padilla S, Gutierrez F, Masia M, Canovas VC, Orozco C. 
AIDS Patient Care STDS. 2005 Jul;19(7):421-4.
Abstract
 
 
Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report
and review of the literature.
Quimby D, Brito MO. 

AIDS Read.
2005 Jul;15(7):357-64.
Abstract
 
Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment-case
report and review of literature.
Malik A, Abraham P, Malik N.
J Infect. 2005 Aug;51(2):E61-5.
Abstract
 
Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study.
Antoniou T, Raboud J, Chirhin S, et al 
HIV Med. 2005 Jul;6(4):284-90
Abstract
 
Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-
containing highly active antiretroviral therapy regimen.
Lacombe K, Pacanowski J, Meynard JL 
AIDS.
2005 Jul 1;19(10):1107-1108.
Abstract
 
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
Mauss S; Berger F, et al  

AIDS
. 19(1):93-95, January 3, 2005.
Abstract
 
Renal Dysfunction With Tenofovir Disoproxil Fumarate-Containing Highly Active Antiretroviral
Therapy Regimens Is Not Observed More Frequently: A Cohort and Case-Control Study.
Jones R, Stebbing J, Nelson M, et al 
J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1489-1495.
Abstract
 
Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil
fumarate.
Guo Y, Fung HB.  

Pharmacotherapy.
2004 Aug;24(8):1089-9
Abstract
 
Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir.
Cicconi P, Bongiovanni M, Melzi S, et al 

Int J Antimicrob Agents.
2004 Sep;24(3):284-5.
Abstract
 
Pancreatic toxic effects associated with co-administration of didanosine and tenofovir
in HIV-infected adults.
Martinez E, Milinkovic A, De Lazzari E, et al 
Lancet.
2004 Jul 3;364(9428):65-67.

Abstract
 
Renal Tubular Dysfunction Associated With Tenofovir Therapy: Report of 7 Cases.
Peyriere H, Reynes J, Rouanet I, et al 
J Acquir Immune Defic Syndr.
2004 Apr 12;35(3):293-300.
Abstract
 
Tenofovir-related nephrotoxicity: case report and review of the literature.
James CW, Steinhaus MC, Szabo S, Dressier RM.  
Pharmacotherapy. 2004 Mar;24(3):415-8.

Abstract
 
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three
cases of renal failure, fanconi syndrome, and nephrogenic diabetes insipidus.
Karras A, Lafaurie M, Furco A,  et al.
Clin Infect Dis 2003 Apr 15;36(8):1070-3
Abstract
 
Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral
 regimen containing Didanosine.
Murphy MD, O'Hearn M, Chou , et al.

Clin Infect Dis 2003 Apr 15;36(8):1082-5

Abstract
 
Fanconi syndrome and renal failure induced by tenofovir: a first case report.
Verhelst D, Monge M, Meynard JL, et al. 
Am J Kidney Dis 2002 Dec;40(6):1331-3
Abstract

Thyroid Disorders
 

 
Vitamin D3 Decreases Parathyroid Hormone in HIV-Infected Youth Being Treated With Tenofovir:
A Randomized, Placebo-Controlled Trial.
Havens PL, Stephensen CB, Hazra R,  et al
Clin Infect Dis
. 2012 Jan 19. 
Abstract

Tenofovir-linked hyperparathyroidism is independently associated with the presence
of vitamin D deficiency.
Rosenvinge MM, Gedela K, Copas AJ,  et al  
J Acquir Immune Defic Syndr
. 2010 Aug 15;54(5):496-9.

Abstract
 

Short communication: inadequate vitamin d exacerbates parathyroid hormone
elevations in tenofovir users.
Childs KE, Fishman SL, Constable C,  et al 
AIDS Res Hum Retroviruses
. 2010 Aug;26(8):855-9.

Abstract

 


Tenofovir Main Page Main New/Newsworthy  Home Page      

Tenofovir Journal Citations
Adverse Events